Login

PT Solusi Tunas Pratama Tbk plans to increase its tower count from 1,000 in 2014 to 39,000. 00:10:00

Share On Facebook Share On Twitter

President Director/CEO/Secy, Solusi Tunas Pratama Tbk PT.

Recent Videos

00:10:00
Dryden Gold Secures $20M+ War Chest, Delivers High-Grade Discoveries and Expands Drill Targets Across Gold Rock District|Trey Wasser,CEO & Director,Dryden Gold
00:10:00
Mitchell Services Targets $50–60M EBITDA as Rig Utilization Drives Earnings Upside| Andrew Elf,CEO,Mitchell Services Limited
00:10:00
Lomiko Metals Reports Strong Pre-Feasibility Results with $800M NPV, Advancing High-Growth Graphite Projects|Gordana Slepcev,CEO,Lomiko Metals Inc.4
00:10:00
Generative AI Meets Wet Lab: Absci Accelerates Biologic Development with Hybrid Business Model|Sean McClain,CEO,Absci
00:10:00
Obliva Aims to Transform Lives of Children with Rare Mitochondrial Disorders|Ellen K. Donnelly ,CEO,Abliva AB7
00:10:00
Abionic Repositions Bio-HDL Therapy CCR001 for Rare Kidney and Eye Disorders with Promising Early Results|Cyrille Tupin,CEO,ABIONYX Pharma
00:10:00
Abingdon Health Reports 45% H1 Revenue Growth Amid Strategic Expansion and Large Contract Wins|Dr Chris Hand,Chairman,Abingdon Health
00:10:00
EB-101 Gene Therapy Shows Promising Results in Treating Recessive Dystrophic EB|Vishwas Seshadri,CEO,Abeona Therapeutics
00:10:00
Revolutionizing Trauma Care: How AAP’s Silver Technology is Fighting Deadly Implant Infections|Rubino Di Girolamo,CEO,aap Implantate AG
00:10:00
Revolutionizing Cancer Treatment: Tumor-Agnostic mTOR Targeting Shows Breakthrough Success in Rare and Genetic-Driven Tumors| Neil Desai, Founder, Executive Chairman ,Aadi Bioscience
00:10:00
Millions Affected, No Approved Cure: 89bio Advances New Therapy for NASH|Rohan Palekar,CEO,89bio Inc2
00:10:00
Malaria Prevention Drug Arakoda Positioned to Drive Future Growth for 60 Degrees Pharmaceuticals|Geoffrey Dow,President,60 Degrees Pharmaceuticals
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4basebio CEO Heikki Lanckriet Unveils Vision for Next-Generation Synthetic DNA and Gene Therapy Components|Heikki Lanckriet,CEO,4basebio
00:10:00
Jim Woody on Leading 180 Life Sciences: Advancing Breakthrough Biologic Therapies for Inflammation, Fibrosis, and Pain|Dr. Jim Woody,CEO,180 Life Sciences

Suggestions

00:10:00
NYC Benchmarking Update: Key Considerations for August Deadline
00:10:00
An analyst discusses Naver and SK Telecom and their strategies.
00:10:00
Our history with Chemring Energetic Devices | Michael Ord, Group Chief Executive, CHEMRING GROUP 7% PRFBC88:LSE
00:10:00
Uncovering Hidden Assets in Divorce: Expert Tips and Advice
00:00:00
Noxopharm details science-driven strategy in new investor presentation - Dr Gisela Mautner Chief Executive Officer and Managing Director, Noxopharm Ltd
00:10:00
Luke Martins on Turning Investing into the Ultimate Side Hustle | Luke Martins, CFP®, Financial Planning Coach, Old Mutual Wealth
00:10:00
Addressing Lead Ammunition Ban Concerns and Compliance Challenges
00:10:00
Mike Gold on Intermedia's Strategic Growth and Market Evolution | Michael Gold, CEO, Intermedia Partners.
00:10:00
CEO outlines Q1 performance and future focus, covering occupancy rates, and market conditions, facilitating investor engagement | Stefan Dahlbo , CEO , Fabege AB.
00:10:00
Committed to delivering optimal solutions by leveraging their industry experience|Jakob Dock, Senior Director, Oracle Partners
00:10:00
Matt O'Donnell's Journey: Selling His Business to a Private Equity Strategic Partner
00:10:00
focused on SaaS enterprise software and B2B marketplaces|Christoph Janz,Managing Partner,Point Nine

© 2017 - Neuhu+